Cargando…

Nano/microparticle Formulations for Universal Influenza Vaccines

Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendy, Dylan A., Amouzougan, Eva A., Young, Isabella C., Bachelder, Eric M., Ainslie, Kristy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741137/
https://www.ncbi.nlm.nih.gov/pubmed/34997352
http://dx.doi.org/10.1208/s12248-021-00676-9
_version_ 1784629423017820160
author Hendy, Dylan A.
Amouzougan, Eva A.
Young, Isabella C.
Bachelder, Eric M.
Ainslie, Kristy M.
author_facet Hendy, Dylan A.
Amouzougan, Eva A.
Young, Isabella C.
Bachelder, Eric M.
Ainslie, Kristy M.
author_sort Hendy, Dylan A.
collection PubMed
description Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More conserved universal influenza antigens like M2 ectodomain (M2e) and the stalk region of hemagglutinin (HA stalk) have been used clinically but often suffer from low antigenicity. To increase antigenicity, universal antigens have been formulated using nano/microparticles as vaccine carriers against influenza. Utilizing polymers, liposomes, metal, and protein-based particles, indicators of immunity and protection in mouse, pig, ferrets, and chicken models of influenza have been shown. In this review, seasonal and universal influenza vaccine formulations comprised of these materials including their physiochemical properties, fabrication, characterization, and biologic responses in vivo are highlighted. The review is concluded with future perspectives for nano/microparticles as carrier systems and other considerations within the universal influenza vaccine delivery landscape. [Figure: see text]
format Online
Article
Text
id pubmed-8741137
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-87411372022-01-10 Nano/microparticle Formulations for Universal Influenza Vaccines Hendy, Dylan A. Amouzougan, Eva A. Young, Isabella C. Bachelder, Eric M. Ainslie, Kristy M. AAPS J Review Article Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More conserved universal influenza antigens like M2 ectodomain (M2e) and the stalk region of hemagglutinin (HA stalk) have been used clinically but often suffer from low antigenicity. To increase antigenicity, universal antigens have been formulated using nano/microparticles as vaccine carriers against influenza. Utilizing polymers, liposomes, metal, and protein-based particles, indicators of immunity and protection in mouse, pig, ferrets, and chicken models of influenza have been shown. In this review, seasonal and universal influenza vaccine formulations comprised of these materials including their physiochemical properties, fabrication, characterization, and biologic responses in vivo are highlighted. The review is concluded with future perspectives for nano/microparticles as carrier systems and other considerations within the universal influenza vaccine delivery landscape. [Figure: see text] Springer International Publishing 2022-01-07 /pmc/articles/PMC8741137/ /pubmed/34997352 http://dx.doi.org/10.1208/s12248-021-00676-9 Text en © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Hendy, Dylan A.
Amouzougan, Eva A.
Young, Isabella C.
Bachelder, Eric M.
Ainslie, Kristy M.
Nano/microparticle Formulations for Universal Influenza Vaccines
title Nano/microparticle Formulations for Universal Influenza Vaccines
title_full Nano/microparticle Formulations for Universal Influenza Vaccines
title_fullStr Nano/microparticle Formulations for Universal Influenza Vaccines
title_full_unstemmed Nano/microparticle Formulations for Universal Influenza Vaccines
title_short Nano/microparticle Formulations for Universal Influenza Vaccines
title_sort nano/microparticle formulations for universal influenza vaccines
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741137/
https://www.ncbi.nlm.nih.gov/pubmed/34997352
http://dx.doi.org/10.1208/s12248-021-00676-9
work_keys_str_mv AT hendydylana nanomicroparticleformulationsforuniversalinfluenzavaccines
AT amouzouganevaa nanomicroparticleformulationsforuniversalinfluenzavaccines
AT youngisabellac nanomicroparticleformulationsforuniversalinfluenzavaccines
AT bachelderericm nanomicroparticleformulationsforuniversalinfluenzavaccines
AT ainsliekristym nanomicroparticleformulationsforuniversalinfluenzavaccines